Exploring EGFR Mutations and Prevalence in Non-Small Cell Lung Cancer

Cara Chang, PharmD, BCOP, examines the prevalence of EGFR positivity, provides an overview of clinically relevant EGFR mutations, and discusses therapeutic options for EGFR-positive mutations.

Now Viewing

EP: 1.Exploring EGFR Mutations and Prevalence in Non-Small Cell Lung Cancer

EP: 2.Examining Key Data from the FLAURA2 and MIRAPOSA Trials

EP: 3.Analyzing the MARIPOSA-2 Trial Data’s Impact on Clinical Practice

EP: 4.Exploring Key Insights from the PAPILLON Trial

EP: 5.Common Adverse Reactions to EGFR Therapy

EP: 6.Expert Insights on Managing Amivantamab Infusion Reactions, Dosing, and Medication

EP: 7.Impact of Emerging Therapies on Outcomes for EGFR-Mutated NSCLC

To set the stage for EGFR+ metastatic NSCLC, what is the prevalence of EGFR positivity? What are the different EGFR mutations that are relevant to treatment decisions, and what are their respective frequencies?
Provide a broad overview of therapy options in EGFR+ mutations, including a comparison of mechanism of action between 1st, 2nd, and 3rd generation oral TKIs as well as the bispecific antibody amivantamab.
1. Discuss the dual targets of amivantamab, and the role of MET-targeted therapies in overcoming EGFR therapy resistance
The NCCN guideline has undergone several updates regarding the management of various mutation groups. Beginning with our most prevalent mutations, EGFR Ex19del or exon 21 L858R, what are the currently recommended treatment options for initial management?